Αρχική World News FDA approves lutetium Lu 177 vipivotide tetraxetan with ARPI therapy for metastatic... World News FDA approves lutetium Lu 177 vipivotide tetraxetan with ARPI therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer Από Ogkologos - 23 Σεπτεμβρίου, 2026 302 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAddition study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than... 22 Μαΐου, 2024 Scientists uncover how incurable skin cancer resists treatment at the end... 29 Μαρτίου, 2023 Imiquimod is a Safe and Effective Alternative to Surgery for Vulvar... 5 Μαΐου, 2022 Metastatic Breast Cancer Patient Denied Chemotherapy Treatment During COVID-19 Outbreak 20 Μαρτίου, 2020 Φόρτωση περισσοτέρων HOT NEWS What to Know About Exercising During Prostate Cancer: An Expert Q&A EMA Recommends Granting a Marketing Authorisation for Capmatinib Updated Oncogene-Addicted mNSCLC Living Guideline v1.3 Coping With Advanced Melanoma and a Second Cancer Diagnosis: A Survivor’s...